This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Why BioDelivery Sciences (BDSI) Stock Hit a One-Year High Today

NEW YORK (TheStreet) -- BioDelivery Sciences (BDSI - Get Report) surged Monday to a 52-week high of $14.38 after the company announced in conjunction with Endo that their experimental painkiller BEMA buprenorphine was effective in a second late-stage trial.

The trial tested the drug against a placebo in 511 patients on regular opioid therapy. Data from the first late-stage trial in January revealed the drug significantly reduced chronic pain in patients who do not regularly take opioids.

BioDelivery and Endo signed an agreement in Jan. 2012 to develop the drug for chronic pain treatment. Endo will make a milestone payment of $10 million to BioDelivery as part of the deal.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

BioDelivery was up 10.4% to $13.24 at 12:14 p.m. More than 5.2 million shares had changed hands, compared to the average volume of 761,227.

BDSI Chart

BDSI data by YCharts

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
SYM TRADE IT LAST %CHG
BDSI $6.19 -3.90%
AAPL $110.96 3.00%
FB $88.94 2.00%
GOOG $608.00 1.70%
TSLA $243.41 2.00%

Markets

Chart of I:DJI
DOW 16,257.18 +198.83 1.24%
S&P 500 1,934.81 +20.96 1.10%
NASDAQ 4,703.0360 +66.9310 1.44%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs